TheV-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control

• Published in: Endocrine practice Vol. 18; no. 5; pp. 660 - 667
• Main Authors: Rosenfeld, Cheryl R, Bohannon, Nancy J, Bode, Bruce, Kelman, Adam S, Mintz, Shari N, Schorr, Alan B, Sandberg, Marc I, Nambi, Sridhar, Agarwala, Sumon K, Leichter, Steven B, Larrabee, Bart, Shi, Lei, Strange, Poul
• Format: Journal Article
• Language: English
• Published: United States 01.09.2012
• Subjects: Adult; Aged; Female; Humans; Hypoglycemic Agents - administration & dosage; Insulin - administration & dosage; Insulin Infusion Systems - psychology; Male; Middle Aged; Retrospective Studies
• ISSN: 1934-2403
• DOI: 10.4158/EP11362.OR

To describe patient perceptions regarding their experience and to report findings in a retrospective analysis of glycemic control in a cohort of patients who used the V-Go, a mechanical, 24-hour disposable, subcutaneous continuous insulin delivery device that delivers a preset basal infusion rate and on-demand insulin. Patients used the V-Go and answered telephone surveys about their perception of device use. Corresponding clinical data were retrospectively collected before V-Go initiation, after 12 weeks of use, at the end of treatment, and 12 weeks after discontinuation. Analyses were performed with nonparametric statistical tests. Twenty-three patients participated. Mean values of the following characteristics were documented: patient age, 61 years; body mass index, 30 kg/m2; diabetes duration, 16 years; duration of insulin therapy, 7 years; average duration of V-Go use, 194 days; and mean total daily insulin dose, 50 U at baseline, 46 U while on V-Go, and 51 U after stopping V-Go treatment. Mean patient rating of the overall experience was 9.1 at 12 weeks on a scale from 1 to 10 (10 being most positive). Mean hemoglobin A1c value decreased from baseline (8.8% to 7.6%; [P = .005]) while using the V-Go, and it increased to 8.2% after treatment. Fasting plasma glucose trended from 205 mg/dL at baseline to 135 mg/dL while using V-Go and increased to 164 mg/dL after V-Go was stopped. Weight was essentially unchanged. No differences in hypoglycemic events were found; site reactions were minor. Glycemic control improved when patients were switched to the V-Go for insulin delivery, and it deteriorated when the V-Go was discontinued.